LONDON (Reuters) – Novo Nordisk reported on Tuesday that patients on Wegovy sustained a 10% weight loss over four years.
Novo shared the long-term data at the European Congress on Obesity in Venice, Italy. The data was gathered from a substantial study, with many results already published last year.
“This is the longest study we’ve conducted so far of semaglutide for weight loss,” Martin Holst Lange, Novo’s head of development, said in an interview, referring to the active ingredient in Wegovy and the company’s diabetes drug Ozempic.
“We see that once the majority of the weight loss is accrued, you don’t go back and start to increase in weight if you stay on the drug,” he added.
The data could strengthen the company’s argument for Wegovy reimbursement, countering claims of it being merely a lifestyle drug.
Dr. Simon Cork, Senior Lecturer in Physiology from Anglia Ruskin University, said Britain’s public health service’s decision to limit coverage of the medicine to two years was “because of questionable long-term effectiveness”.
Additionally, Novo Nordisk’s trial findings highlight the importance of ongoing research and innovation in addressing the global obesity epidemic. As the prevalence of obesity continues to rise worldwide, there is an urgent need for effective and sustainable weight loss solutions. Wegovy’s success provides hope for those battling obesity.
Furthermore, it signifies progress in the field. Consequently, it heralds a brighter future for weight management.
read more
image source
